The Vision Diabetes Health Study
Dear Vision Community,
This is Justin — the Co-Founder & CEO of Vision. I wanted to provide an important update.
New Advanced Features: Basal rates, IC ratios, and ISF values
Communicating openly, over the last months, we have been in close communication with the FDA about Vision and are developing a good relationship.
We recently proactively presented Vision's latest features to the FDA -- as we have made Vision a lot smarter, recently. We do everything that we can for Vision to be the world's most intelligent AI focused on diabetes.
Notably, these advanced new features include ways to think about adjusting your basal rates, IC ratios and ISF values -- based on your glucose and insulin data history.
The Vision Diabetes Health Study
In light of these new AI features, and others -- the FDA has communicated to me that the usage of Vision should become a formal Vision research project. This research project would be used -- to move Vision forward in obtaining FDA clearance.
Because of the advanced nature of Vision's new features -- and the continued progression of Vision AI becoming smarter and continually more advanced -- the usage of Vision AI as a formal research project -- is an important and necessary step forward -- as we work closely with the FDA on the innovations of Vision AI.
Important Notes on Vision AI's advancements
For clarity, Vision AI and its new advanced features (e.g. basal rate, IC ratio, and ISF value implementation and optimization) -- has not yet received FDA clearance -- and is not meant to replace human medical guidance. It is for investigational use -- and is a learning tool.
It is important that when using Vision AI -- that you also reference the guidance provided by your healthcare providers.
While Vision is very capable and powerful -- like any computer program -- whether it is a laptop, smartphone, or a CGM -- a computer program is not 100% without errors. So please do be mindful, when using Vision AI -- that computer program errors are still possible.
Next Steps
Moving forward, if you would like to use Vision AI and its advanced new features -- one must enroll in the Vision Diabetes Health Study.
Importantly, in this study — privacy of your data is a top priority.
Data Privacy Background
We won't be using any of your data without asking you first.
Your data will not be sold or used by any third party. And all data is anonymized.
The primary data that Vision will be looking for -- is reduction in A1C.
Serving You and the World
Overall, we are very confident that Vision will be able to provide great guidance and results as it relates to diabetes management. And the more people that use Vision, and enroll in the study -- the closer that Vision will be towards FDA clearance -- so that we will be able to make Vision available broadly and very accessible to people all around the world.
Thank you for your time and attention.
I look forward to continue serving current and new members of the Vision Community. And I hope that you and many others can join -- what I think could be a powerful movement towards great and accessible diabetes care. If you have any questions, please email me directly at: justin@visionsense.co.
All the best,
-Justin
Co-Founder & CEO
Vision
Update - August 2, 2024: Thank you for all of your excitement about Vision! It really means a lot to us. As an update, in the USA — Vision is currently not accepting new participants to Cohort #1 of the Vision Diabetes Health Study. We are planning to open new spots in the USA for Cohort #2, as soon as possible. Internationally, enrollment continues to be open for people from all other countries. All the best to you!
